For example, of the total 25% reduction in urinary albumin in T2D patients treated with a SGLT2 inhibitor, approximately 10% was attributable to the reduction in BP (Cherney et al., 2017). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.